Zolbetuximab with chemotherapy for advanced biliary tract cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called zolbetuximab, which targets a protein (Claudin 18.2) on cancer cells, combined with standard chemotherapy, for advanced bile duct or gallbladder cancer. The goal is to see if this combination helps shrink or control the cancer better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are physically able to do daily activities (ECOG status 0 or 1).
- Your cancer is advanced (cannot be removed by surgery) or has spread to other parts of the body.
- You have had no more than one prior chemotherapy for your advanced cancer.
- Your tumor tests positive for a protein called Claudin 18.2 (this is done on a biopsy sample).
- You have adequate blood, kidney, and liver function (your doctor will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
This trial tests a combination of three drugs (zolbetuximab, paclitaxel, and ramucirumab) for people with advanced stomach or esophagus cancer that has a specific protein called CLDN18.2. It may be an option if you've already had one standard treatment.
This trial is for people with advanced stomach cancer that has a specific protein called Claudin18.2 and is HER2-negative. It tests whether continuing zolbetuximab—a drug that targets this protein—can help control the cancer.
This trial is looking at a drug called zolbetuximab, given with chemotherapy, for people with a certain type of stomach or gastroesophageal junction cancer that has spread and has high levels of a protein called claudin 18.2. The goal is to see how well it works in real-world settings.
This study tests a new drug called zolbetuximab added to standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer. It may help slow the cancer's growth.
This study looks at how well zolbetuximab works when combined with chemotherapy in people with advanced stomach or gastroesophageal junction cancer. It aims to help doctors understand the best ways to use this treatment in everyday practice.
Hear when a new Advanced Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.